SageMedic

SageMedic is a private, commercial-stage diagnostics company focused on functional precision oncology. Its core technology, the SAGE Oncotest™, utilizes live 3D microtumor cultures from patient biopsies to empirically test drug sensitivity, addressing a critical gap left by genomic testing alone. The company operates a CLIA-certified lab in Redwood City, CA, offering the test nationwide under physician order, positioning it as a service-based business in the growing field of personalized cancer treatment. Leadership includes physician-founders and seasoned advisors, driving a vision to improve patient outcomes by de-risking therapy selection.

Proprietary functional diagnostic platform using live patient-derived 3D microtumors that retain tumor microenvironment and heterogeneity for empirical drug sensitivity testing against a panel of FDA-approved oncology therapies.

SageMedic competes in the functional precision oncology space against other companies offering ex vivo drug sensitivity testing platforms. It also competes indirectly with comprehensive genomic profiling companies and must convince oncologists to adopt an additional testing modality alongside standard genomic tests.